Accessibility Menu
Matinas BioPharma logo

Matinas BioPharma

(NYSEMKT) MTNB

Current Price$0.34
Market Cap$4.70MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2014)-99%
5 Year-99%
1 Year-64%
1 Month-52%
Matinas BioPharma last closing stock price
MetricPriceDate
Last closeUSD 0.342026-07-17
Matinas BioPharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-54.51%USD 0.762026-07-10
1 month-51.61%USD 0.712026-06-17
3 month-31.28%USD 0.502026-04-17
Year to date-41.37%USD 0.592025-12-31
1 year-64.21%USD 0.962025-07-17
3 year-98.07%USD 17.802023-07-18
5 year-99.05%USD 36.002021-07-16
Since inception-99.47%USD 65.002014-07-21

Matinas BioPharma Financials at a Glance

Market Cap

$4.70MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$11.23M

EPS (TTM)

-$2.02

P/E Ratio

-0.17

Dividend

$0.00

Beta (Volatility)

1.19 (Average)

Price

$0.34

Volume

7,152

Open

$0.34

Previous Close

$0.34

Daily Range

$0.32 - $0.34

52-Week Range

$0.31 - $3.09

Estimated Earnings Date

Aug 13, 2026

MTNB News

Tryglicerides

Why Matinas BioPharma Stock Crashed Today

Keith SpeightsFeb 1, 2021
A medical professional using a microscope

Why Matinas BioPharma Holdings Shot Almost 28% Higher Today

Eric VolkmanJan 4, 2021
stock sliding chalkboard

Here's Why Matinas Biopharma Shares Fell as Much as 23.6% Today

Maxx ChatskoJan 10, 2020
stock down angry fist

Here's Why Matinas BioPharma Shares Lost as Much as 16.9% Today

Maxx ChatskoJan 7, 2020
man with cup listening to wall GettyImages-511535378

Why Matinas BioPharma Tumbled 13.4% Today

Todd CampbellDec 16, 2019
stock-market-investor-hiding-under-laptop-getty

Here's Why Matinas BioPharma Holdings Inc. Is Losing Ground Today

Cory RenauerJun 26, 2017

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Matinas BioPharma

Matinas develops medicines that help treat serious infections and heart conditions. Its main products aim to make treatments easier for patients who need them most. The company uses a special technology to deliver drugs by mouth instead of injection.

What’s in the Medicine Cabinet?

  • MAT2203 (Oral Amphotericin B): Oral treatment for invasive fungal infections, especially for patients with weak immune systems. 0% of revenue (no product sales).
  • LYPDISO: Omega-3 fatty acid product for heart and metabolic health. 0% of revenue (no product sales).
  • MAT2501: Oral antibiotic for drug-resistant bacterial infections, including rare lung diseases. 0% of revenue (no product sales).
  • Lipid Nanocrystal (LNC) Platform: Technology that helps deliver medicines by mouth, targeting drugs usually given by injection.
  • Research Collaborations: Joint projects with government and industry partners to explore new drug delivery methods.

Growth Spurts and Strategic Moves

  • Formed research partnership with National Institute of Allergy and Infectious Diseases for remdesivir in 2023.
  • Started feasibility collaboration with Genentech for oral drug formulations in 2023.
  • Raised $10 million in April 2024 and $3.3 million in early 2025 through equity offerings.
  • Paused internal drug development and reduced workforce by 80% in October 2024 to conserve cash.
  • Reverse stock split (1-for-50) in August 2024 to maintain NYSE listing.

Why Matinas Stands Out (Without the Lab Coat)

Matinas’s technology allows drugs usually given by injection to be taken by mouth, which can make treatment easier and safer for patients. The company holds patents protecting its delivery platform and main drug candidate until at least 2033. Its focus is now on finding partners to advance its lead product, MAT2203, while keeping costs low.

Five Things You Need to Know

  • Revenue was $0 in 2025, unchanged from 2024 and 2023.
  • Net loss was $10.3 million in 2025, down 57.3% from 2024.
  • Cash used in operations was $7.0 million in 2025, down 56% from 2024.
  • Cash and equivalents were $4.0 million at December 31, 2025, down 45% from 2024.

Bottom Line

Matinas has shifted from active drug development to seeking partners for its main product. The company’s future depends on successful collaboration or sale of its technology.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

4

CEO

Jerome D. Jabbour

Website

www.matinasbiopharma.com

Headquarters

Bedminster, NJ 07921, US

MTNB Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-204.27%

Return on Capital

-112.55%

Return on Assets

-191.15%

Earnings Yield

-5.88%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$4.70MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

13.69M

Volume

7.15K

Avg. Volume

517.56K

Financials (TTM)

Gross Profit

-$227.00K

Operating Income

-$6.95M

EBITDA

-$9.72M

Operating Cash Flow

-$6.61M

Capital Expenditure

$0.00

Free Cash Flow

-$6.61M

Cash & ST Invst.

$2.45M

Total Debt

$1.19M

Matinas BioPharma Performance Analysis

Matinas BioPharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 3,188,0009464.1%
20232023-12-31USD 1,096,000-65.6%
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Matinas BioPharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Matinas BioPharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -4.84-14.0%
20232023-12-31USD -5.289.0%
20242024-12-31USD -4.98-5.6%
20252025-12-31USD -2.00-59.8%
Matinas BioPharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-212.1%
Q32025-09-3061.2%
Q42025-12-3125.0%
Q12026-03-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$74.00K

+12.9%

Gross Margin

0.00%

N/A

Market Cap

$4.70MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.18M

N/A

Employees

4

N/A

Net Income

-$1.92M

-16.0%

EBITDA

-$1.85M

-12.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$2.45M

-64.6%

Total Debt

$1.19M

-56.2%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$469.00K

-75.6%

Short Term Debt

$720.00K

-9.3%

Return on Assets

-1.91%

N/A

Return on Invested Capital

-1.85%

N/A

Free Cash Flow

-$1.60M

+20.2%

Operating Cash Flow

-$1.60M

+20.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ADXNAddex Therapeutics Ltd
$5.70-4.12%
CDIOCardio Diagnostics Holdings, Inc.
$1.72+1.78%
KTTAPasithea Therapeutics Corp.
$0.45-1.57%
ADILAdial Pharmaceuticals, Inc.
$2.80+0.36%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$95.04-0.02%
PATHUiPath
$12.15+0.01%
JOBYJoby Aviation
$7.23-0.01%
TAT&T
$21.81-0.01%

Questions About MTNB

What is the current price of Matinas BioPharma?

Matinas BioPharma is trading at $0.34 per share.

What is the 52-week range for Matinas BioPharma?

Over the past 52 weeks, Matinas BioPharma has traded between $0.31 and $3.09.

How much debt does Matinas BioPharma have?

As of the most recent reporting period, Matinas BioPharma reported total debt of $1.19M.

How much cash does Matinas BioPharma have on hand?

Matinas BioPharma reported $2.45M in cash and cash equivalents in its most recent financial results.

What is Matinas BioPharma’s dividend yield?

Matinas BioPharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services